- Home
- FNWD vs DMAC Comparison
FNWD vs DMAC Comparison
Compare FNWD & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNWD
- DMAC
- Stock Information
- Founded
- FNWD 1994
- DMAC 2000
- Country
- FNWD United States
- DMAC United States
- Employees
- FNWD N/A
- DMAC 28
- Industry
- FNWD Savings Institutions
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- FNWD Finance
- DMAC Health Care
- Exchange
- FNWD Nasdaq
- DMAC Nasdaq
- Market Cap
- FNWD 133.3M
- DMAC 178.0M
- IPO Year
- FNWD N/A
- DMAC N/A
- Fundamental
- Price
- FNWD $29.69
- DMAC $4.13
- Analyst Decision
- FNWD Buy
- DMAC Strong Buy
- Analyst Count
- FNWD 1
- DMAC 2
- Target Price
- FNWD $34.00
- DMAC $8.00
- AVG Volume (30 Days)
- FNWD 6.1K
- DMAC 102.4K
- Earning Date
- FNWD 07-23-2025
- DMAC 05-13-2025
- Dividend Yield
- FNWD 1.64%
- DMAC N/A
- EPS Growth
- FNWD N/A
- DMAC N/A
- EPS
- FNWD 0.78
- DMAC N/A
- Revenue
- FNWD $61,430,000.00
- DMAC N/A
- Revenue This Year
- FNWD N/A
- DMAC N/A
- Revenue Next Year
- FNWD $7.07
- DMAC N/A
- P/E Ratio
- FNWD $37.63
- DMAC N/A
- Revenue Growth
- FNWD N/A
- DMAC N/A
- 52 Week Low
- FNWD $23.50
- DMAC $2.14
- 52 Week High
- FNWD $33.50
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- FNWD 35.99
- DMAC 51.10
- Support Level
- FNWD $30.00
- DMAC $4.00
- Resistance Level
- FNWD $30.40
- DMAC $4.33
- Average True Range (ATR)
- FNWD 0.40
- DMAC 0.27
- MACD
- FNWD -0.17
- DMAC 0.02
- Stochastic Oscillator
- FNWD 0.00
- DMAC 50.71
About FNWD Finward Bancorp
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.